Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial

Fransson, Per-Anders; Lund, Jo Åsmund; Damber, Jan Erik; Klepp, Olbjørn; Wiklund, Fredrik; Fosså, Sophie D.; Widmark, Anders

doi:10.1016/s1470-2045(09)70027-0

Cited by 71 publications

(45 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A focused literature search conducted by NICE 112 identified three published papers from two new RCTs. 95,113 Only one paper had published full results of the trial at the time of analysis (the SPCG-7 trial 96 ). Six RCTs identified in the NICE prostate cancer guideline 71 have published additional follow-up results with findings in support of combined radiotherapy and hormone therapy.…”

Section: Case Study 1: Full Guideline Model For Prostate Cancermentioning

confidence: 99%

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

Lord

Willis²,

Eatock³

et al. 2013

Health Technology Assessment

View full text Add to dashboard Cite

Section: Case Study 1: Full Guideline Model For Prostate Cancermentioning

confidence: 99%

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

Lord

Willis²,

Eatock³

et al. 2013

Health Technology Assessment

View full text Add to dashboard Cite

“…However, the maintenance of erectile function in these patients is low 4,5 as a result of the wide resection required in high-risk disease. Still, those rates compare favourably with the rates after rt for cT3 disease 42 .…”

Section: Multimodal Approaches To High-risk Prostate Cancermentioning

confidence: 85%

Multimodal Approaches to High-Risk Prostate Cancer

Koupparis

Gleave

2010

Current Oncology

View full text Add to dashboard Cite

Widespread use of testing for prostate-specific antigen (psa) has led to a migration in the stage and grade of prostate cancer (pca), with most men presenting with localized disease. However, 20%-35% of patients still present with high-risk disease (psa > 20 ng/mL, biopsy Gleason score 8-10, or clinical stage T3). Despite advances in various treatment modalities, patients with high-risk disease have a significant chance of recurrence and death after surgery, often because of the presence of early occult metastasis at time of diagnosis. The optimal management of high-risk pca remains controversial. The present article aims to discuss the traditional approaches and the more recent evolution toward multimodal therapies. KEY WORDSUrology, prostate cancer

show abstract

“…The rates of erectile dysfunction do, however, compare favourably to those after RT for clinical T3 disease. 29 A further benefit of primary RP in patients with high-risk clinically localized prostate cancer may be in the subsequent development of metastatic disease. The Southwest Oncology Group (SWOG) 8894 compared orchidectomy to orchidectomy plus flutamide in patients with metastatic disease.…”

Section: Discussionmentioning

confidence: 99%

Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series

Koupparis

Grummet

Hurtado-Coll

et al. 2011

cuaj

View full text Add to dashboard Cite

E156Cite as: Can Urol Assoc J 2011;5(6):E156-E161; http://dx.doi.org/10.5489/cuaj.10057. Epub 2011 Mar 1. AbstractObjective: The objective of this paper is to report on the pathologic and biochemical progression-free outcomes of patients who underwent radical prostatectomy for high-risk localized prostate cancer. Methods: Data was collected prospectively from 299 patients who underwent radical prostatectomy for high-risk clinically localized prostate cancer by 2 surgeons at a single institution. High risk was defined as 1 or more of 3 adverse factors: prostate-specific antigen (PSA) >20, biopsy Gleason score 8 to 10 and clinical stage T3. PSA recurrence was defined as PSA >0.4 ng/mL or any salvage therapy. Results: Median age was 63.3 years (46.1-75.9). Median followup was 4.7 years (range 0.5-17.3 years). PSA at diagnosis was >20 ng/mL in 31.4%. Biopsy Gleason score was 8 to 10 in 66.9%. Clinical stage was T3 in 24.4%. 81.6% of patients had a single baseline risk factor, 15.7% had 2 risk factors and 2.7% had all 3 risk factors. Neoadjuvant therapy was administered to 184 patients (61.5%). Pathologic stage was organ-confined in 39.6%, specimenconfined in 26%, non-specimen-confined in 26.4%, and 8% had lymph node positive disease. Overall survival, cancer-specific survival and biochemical progression-free survival was 99%, 99.67% and 70.2%, respectively. Univariate analysis showed that PSA at diagnosis, percentage of cores positive and number of risk factors were predictors of PSA recurrence (p < 0.05). Multivariate analysis showed that PSA at diagnosis was an independent predictor of PSA recurrence (p < 0.05). Conclusion: Radical prostatectomy is associated with favourable biochemical progression-free, clinical and overall survival in selected men with high-risk localized prostate cancer, and should therefore be considered an option in these patients. Baseline PSA >20 ng/mL is a significant independent predictor of PSA recurrence. RésuméObjectif : L'objectif de cet article est de faire rapport sur les résultats quant à la survie sans progression pathologique et biochimique des patients ayant subi une prostatectomie radicale pour traiter un cancer de la prostate localisé à risque élevé. Méthodologie : Les données ont été recueillies de manière prospective chez 299 patients ayant subi une prostatectomie radicale réalisée par 2 chirurgiens dans un même établissement pour traiter un cancer de la prostate à risque élevé cliniquement localisé. Un risque élevé était défini comme au moins 1 des 3 facteurs négatifs suivants : taux d'antigène prostatique spécifique (APS) > 20, score de Gleason de 8 à 10 à la biopsie, stade clinique T3. Une récidive avec anomalie de l'APS a été définie comme un taux d'APS > 0,4 ng/mL ou le recours à tout traitement de sauvetage. Résultats : L'âge médian était de 63,3 ans (46,1 à 75,9). Le suivi médian était de 4,7 ans (0,5 à 17,3 ans). Le taux d'APS au moment du diagnostic était > 20 ng/mL chez 31,4 % des patients. Le score de Gleason à la biopsie était de 8 à 10 dans 66,9 % des cas. Le st...

show abstract

Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial

Cited by 71 publications

References 33 publications

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

Multimodal Approaches to High-Risk Prostate Cancer

Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series

Contact Info

Product

Resources

About